Caprius announces assay development and license..., 2000 WLNR 10279634
`
`12/15/00 Transplant News (Pg. Unavail. Online)
`2000 WLNR 10279634
`
`Transplant News
`Copyright © 2000 Transplant Communications, Inc.
`
`December 15, 2000
`
`Volume 10; Issue 23
`
`Caprius announces assay development and license agreement with Novartis Pharma AG to market Certican.
`
`Caprius, Inc., Fort Lee, NJ, announced that its wholly owned subsidiary, Opus Diagnostics, Inc., has entered into an
`agreement with Novartis Pharma AG, Basel, Switzerland, for Opus to develop and market internationally an assay to
`monitor Certican (everolimus) blood levels.
`
`Certican is a Novartis drug candidate currently in development in late Phase III clinical studies. Caprius says Certican
`is the proliferation signal inhibitor that acts synergistically with Novaratis' Neoral to suppress T-cell proliferation and
`prolong allograft survival. Regulatory approval for Certican is being sought initially for the treatment of renal transplant
`patients.
`
`Opus' test to measure Certican is expected to be used to monitor blood levels of the drug in selected patients, guiding
`physicians to optimize dosage and patient outcomes.
`
`Contact: Beverly Tkaczenko - (201) 592-8838
`
`---- Index References ----
`
`Company: NOVARTIS CONSUMER HEALTH; NOVARTIS (RUSSIA); INNOVATIVE INTERFACES INC;
`CAPRIUS INC; NOVARTIS; NOVARTIS AG; NOVARTIS PHARMA AG
`
`News Subject: (Major Corporations (1MA93); Economics & Trade (1EC26); Licensing (1LI80))
`
`Industry: (Pharmaceuticals Regulatory (1PH03); Pharmaceuticals Joint Development Projects (1PH87); Healthcare
`Regulatory (1HE04); Pharmaceuticals & Biotechnology (1PH13); Clinical Laboratory (1CL83); Healthcare Services
`(1HE13); Healthcare (1HE06); Healthcare Services Regulatory (1HE66); Clinical Diagnostics (1DI45))
`
`Region: (Central Europe (1CE50); Europe (1EU83); Switzerland (1SW77); Western Europe (1WE41))
`
`Language: EN
`
`Other Indexing: (BEVERLY TKACZENKO; III; NOVARTIS; NOVARTIS PHARMA AG) (Caprius; Certican; Opus;
`Opus Diagnostics) (United States; Switzerland)
`
`Keywords: (Business); (Health care industry); (Biological Products); (Alliances, partnerships); (Biological products)
`
` © 2017 Thomson Reuters. No claim to original U.S. Government Works.
`
`1
`
`

`

`Caprius announces assay development and license..., 2000 WLNR 10279634
`
`Company Terms: CAPRIUS INC; NOVARTIS PHARMA AG; OPUS DIAGNOSTICS
`
`Product: Drugs; Biological Product (Except Diagnostic) Manufacturing
`
`Sic: 2830
`
`Naics Code: 325414
`
`Word Count: 174
`
`End of Document
`
`© 2017 Thomson Reuters. No claim to original U.S. Government Works.
`
` © 2017 Thomson Reuters. No claim to original U.S. Government Works.
`
`2
`
`